{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:04:32Z","timestamp":1768417472686,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ejim.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T19:14:46Z","timestamp":1523474086000},"page":"34-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-5213","authenticated-orcid":false,"given":"Daniele","family":"Pastori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Farcomeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Saliola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Del Sole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Violi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Antonio","family":"Casciaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Menichelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Iannucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elio","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Iannilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2018.04.007_bb0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003347","article-title":"Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms","volume":"5","author":"Violi","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2018.04.007_bb0010","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1160\/TH14-10-0859","article-title":"Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula","volume":"113","author":"Sjogren","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2018.04.007_bb0015","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2018.04.007_bb0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ejim.2018.04.007_bb0025","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jama.2017.1371","article-title":"Association of Preceding Antithrombotic Treatment with Acute Ischemic Stroke Severity and in-Hospital Outcomes among Patients with Atrial Fibrillation","volume":"317","author":"Xian","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2018.04.007_bb0030","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"Gallego","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2018.04.007_bb0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22397","article-title":"Quality of anticoagulation with vitamin K antagonists","volume":"38","author":"Bertomeu-Gonzalez","year":"2015","journal-title":"Clin Cardiol"},{"issue":"1247","key":"10.1016\/j.ejim.2018.04.007_bb0040","first-page":"e23","article-title":"Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation","volume":"32","author":"Chan","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2018.04.007_bb0045","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ijcard.2015.08.054","article-title":"Inadequate anticoagulation by vitamin K antagonists is associated with major adverse cardiovascular events in patients with atrial fibrillation","volume":"201","author":"Pastori","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2018.04.007_bb0050","first-page":"2016","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2018.04.007_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164076","article-title":"Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry","volume":"11","author":"Haas","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejim.2018.04.007_bb0060","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control amongst atrial fibrillation patients on warfarin: the SAMe-TT2R2 (Sex female, Age less than 60, Medical history, Treatment strategy [rhythm control], Tobacco use [doubled], Race [doubled] score)","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2018.04.007_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1160\/TH15-04-0350","article-title":"Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study","volume":"115","author":"Martinez","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2018.04.007_bb0070","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1538-7836.2008.03059.x","article-title":"Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?","volume":"6","author":"Gallagher","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2018.04.007_bb0075","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1160\/TH16-12-0961","article-title":"Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients","volume":"117","author":"Rivera-Caravaca","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2018.04.007_bb0080","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1160\/TH16-10-0757","article-title":"Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants","volume":"117","author":"Raparelli","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2018.04.007_bb0085","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.14-2414","article-title":"Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors","volume":"147","author":"Pastori","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2018.04.007_bb0090","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2018.04.007_bb0095","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/j.1538-7836.2010.03996.x","article-title":"Patient characteristics associated with oral anticoagulation control: results of the veterans AffaiRs study to improve anticoagulation (VARIA)","volume":"8","author":"Rose","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2018.04.007_bb0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ebiom.2016.04.013","article-title":"Chronic kidney disease, time in therapeutic range and adverse clinical outcomes in anticoagulated patients with non-valvular atrial fibrillation: observations from the SPORTIF trials","volume":"8","author":"Proietti","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejim.2018.04.007_bb0105","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.recesp.2014.11.022","article-title":"Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors","volume":"68","author":"Anguita Sanchez","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.ejim.2018.04.007_bb0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5551\/jat.35121","article-title":"Anticoagulation stability depends on CHADS2 score and Hepatorenal function in warfarin-treated patients, including those with atrial fibrillation","volume":"24","author":"Odashiro","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ejim.2018.04.007_bb0115","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1253\/circj.CJ-11-0350","article-title":"Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. - a multicenter study of its status and infuential factors","volume":"75","author":"Okumura","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2018.04.007_bb0120","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.02.022","article-title":"Genetic and non-genetic factors affecting the quality of anticoagulation control and vascular events in atrial fibrillation","volume":"26","author":"Park","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.ejim.2018.04.007_bb0125","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijcard.2016.08.224","article-title":"Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease","volume":"223","author":"Pastori","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2018.04.007_bb0130","article-title":"Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2018.04.007_bb0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00380-016-0832-z","article-title":"Ezetimibe enhances and stabilizes anticoagulant effect of warfarin","volume":"32","author":"Hashikata","year":"2017","journal-title":"Heart Vessels"},{"key":"10.1016\/j.ejim.2018.04.007_bb0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/qjmed\/hcr136","article-title":"Risk factors of vitamin K antagonist overcoagulation","volume":"105","author":"Marie","year":"2012","journal-title":"QJM"},{"key":"10.1016\/j.ejim.2018.04.007_bb0145","doi-asserted-by":"crossref","unstructured":"Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2015; 47:4\u201311.1","DOI":"10.1016\/j.dld.2014.07.170"},{"key":"10.1016\/j.ejim.2018.04.007_bb0150","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/pds.3881","article-title":"The potential drug-drug interaction between proton pump inhibitors and warfarin","volume":"24","author":"Henriksen","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejim.2018.04.007_bb0155","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000637","article-title":"Efficacy and safety of proton pump inhibitors in the long-term aspirin users: a meta-analysis of randomized controlled trials","volume":"24","author":"Dahal","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.ejim.2018.04.007_bb0160","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/clc.21969","article-title":"Atrial fibrillation and acid reflux disease","volume":"35","author":"Velagapudi","year":"2012","journal-title":"Clin Cardiol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518301468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518301468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T01:18:58Z","timestamp":1571102338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620518301468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":32,"alternative-id":["S0953620518301468"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2018.04.007","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}